Press Releases

Press Releases

  • Jun 2, 2021
    NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021

    READ PRESS RELEASE

  • May 28, 2021
    NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference on June 1

    READ PRESS RELEASE

  • May 18, 2021
    NLS Pharmaceutics Announces New Study Data Confirming Mazindol’s Unique Orexin Pathway Activation for Treating Narcolepsy

    READ PRESS RELEASE

  • May 5, 2021
    NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)

    READ PRESS RELEASE

  • Mar 29, 2021
    NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer

    READ PRESS RELEASE

  • Mar 29, 2021
    NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

    READ PRESS RELEASE

  • Mar 13, 2021
    NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)

    READ PRESS RELEASE

  • Feb 25, 2021
    NLS Pharmaceutics to Participate in Upcoming Investor Conferences

    READ PRESS RELEASE

  • Feb 2, 2021
    NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering

    READ PRESS RELEASE

  • Jan 28, 2021
    NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering

    READ PRESS RELEASE

  • Jan 21, 2021
    NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy

    READ PRESS RELEASE